All News

AOSD.temp_.jpg

Disease Activity Criteria for Adult-Onset Still's Disease: EULAR Points to Consider

Jack Cush, MD

EULAR has published a "points to consider" (PtCs) guidance on the development of criteria for the assessment of the disease activity in adult-onset Still’s disease (AOSD).

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Optimizing Hydroxychloroquine Blood Levels in Lupus

Jack Cush, MD

A large observational cohort study suggests that monitoring hydroxychloroquine (HCQ) blood levels is effective in systemic lupus erythematosus (SLE) patients with a target therapeutic range (for HCQ level monitoring) of 750-1150 ng/ml.

Read Article
purpura

B Cell Targeting in Idiopathic Thrombocytopenic Purpura

EurekAlert!

The New England Journal of Medicine  has published a phase III clinical trial showing that a B cell targeting monoclonal antibody, ianalumab, was effective in more than half of the patients with primary immune thromboc

Read Article
labs.tubes_.jpg

British Society of Rheumatology Guideline for Monitoring DMARDs

Jack Cush, MD

The British Society of Rheumatology has published an update to their previous 2017 BSR/BHPR guideline regarding the use and monitoring of DMARDs (disease-modifying anti-rheumatic drugs) used to treat systemic autoimmune rheumatic diseases (SARDs). 

Read Article
Cancer.risk_.jpg

Hematologic Malignancies Increased in Systemic Sclerosis

Jack Cush, MD

Swedish national study found that among a cohort of systemic sclerosis (SSc) patients a two-fold increase risk of hematological malignancies was seen.

Read Article
RheumNow Podcast square

Turkey Tryptophan (11.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?

Read Article
Stills,continuum

Treating Refractory Still's Disease

Jack Cush, MD

A full read systematic review article examined treatment options for difficult to manage systemic juvenile idiopathic arthritis, or Still’s disease.

Read Article
Reefer Madness (12.12.2025) Dr. Jack Cush reviews the news, journal and regulatory reports from this past week on RheumNow. B cell drugs in SLE and ITP, biomarkers in GCA & PSS and great videos by APPs. https://t.co/SKEYlhTfLz https://t.co/mBX4GIQxKe

Links:

Dr. John Cush RheumNow ( View Tweet)
PSS & Biomarkers: Dutch international scleroderma trial of 21 pts showed that cartilage oligomeric matrix protein (COMP), and collagen type IV alpha 1 (COL4A1) significantly correlated with modified Rodnan skin score; COMP were associated with mRSS change (r = 0.013) https://t.co/E7SgmIiYmn
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey> In RA, seropositivity correlates best with what?

Dr. John Cush RheumNow ( View Tweet)

Simple, low-cost strategy to Dx/Prognose GCA using CBC components NLR & PLR. 119 GCA vs 131 non-GCA pts - All CBC biomarkers signif assoc w/ ESR & CRP, but ESR/CRP did not predict mortality over time; YET mortality signif predicted by PLR, NLR, MLR (P value <  0.044) https://t.co/96Q7jDAiWt
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey> What is the Sensitivity of the ANA test?

Dr. John Cush RheumNow ( View Tweet)

I agree that multiple assessments are needed to Dx NP-SLE; but my order of preference (for Dx yield) is: A) Hx c/w cerebritis; B) imaging to r/o other causes; C) CSF IgG index w/ Q albumin

Dr. John Cush RheumNow ( View Tweet)

2018 NHANES population survey of 28,040 individuals, 4168 (14.32%) identified with sleep disorders, and 1589 (4.28%) had #RA. Thus, sleep disorders were significantly associated with increased odds of RA (OR = 1.76, 95% CI: 1.46–2.13, P < 0.001). https://t.co/9O2MsLvwVe https://t.co/cBsm8Jt8Ks

Links:

Dr. John Cush RheumNow ( View Tweet)
CBC & Psoriasis - case–control study 60 pts: 30 PsA & 30 PSO pts showed that PsA showed elevated WBCs, neutrophils, monocytes & inflammatory markers (NLR, MLR, SII, SIRI, & decr PMR (all p < 0.001). NLR 100% Dx accuracy (AUC = 1.000). WBC > 6.7, MLR > 0.17, & PMR ≤ 503 were https://t.co/AB7iFiMuSM
Dr. John Cush RheumNow ( View Tweet)
A New Disease Activity Score for Antiphospholipid Syndrome? APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as thrombotic, microvascular and https://t.co/G2xGtOPmwb
Dr. John Cush RheumNow ( View Tweet)
Subclinical Cardiac Dysfunction in Gout. ECHO study of 202 hyperuricemic (100 gout vs 102 asympt [asymSUA]) pts. VS. asymSUA, Gout pts had signific more LV Diastolic Dysfunc (31% vs 11%), lower LV ejection Fx (60 vs 65); questioning need for tailored CV monitoring in ^SUA pts https://t.co/gCOKKk7H05
Dr. John Cush RheumNow ( View Tweet)
Vitamin D and Lupus Outcomes (11.21.2025) Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. https://t.co/M2e4kMi5H7 https://t.co/wEcAjWJSk7

Links:

Dr. John Cush RheumNow ( View Tweet)
A New Disease Activity Score for Antiphospholipid Syndrome? APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as thrombotic, microvascular and https://t.co/eouynDPLUX
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study adult RA patients shows that TRIPLE Positivity (RF + /ACPA + /ANA +) was consistently associated with higher disease activity at baseline and 12 months of follow-up and lower rates of sustained remission compared to RF + /ACPA + /ANA- https://t.co/l2TQDShFYi
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×